Thanks for the info. At least we are seeing movement in this case. Fingers crossed for AMRN.
You got that right; they've been putting out runners like they were organizing a marathon. Undervalued and overlooked companies are always on the menu!
You post so many threads and you are the only one on them. I saw one yesterday with 7 replies and all of the replies were you. How sad.
Amazing how geniuses just pop up out of the clear blue every morning on this board to tell us how smart they think they are. So far, none of them seems to have a clue....
There is an audio podcast which is worth listening too.
Type 2 diabetics have many options today.
One thing you fail to consider is that Type 2 diabetics can get Omega 3 today. They can get prescription Omega 3 or non prescription Omega 3. They can get prescription pure EPA and non prescription pure EPA.
All options of Omega 3 products are available today. Nobody wants them. We all know what Omega 3s do, and Reduce-it results will simply reinforce what we already know. And, nobody cares.
So, why is it that no Type 2 diabetics (and none of their physicians) use Omega 3s today? What would they have to lose? And still, nobody uses Omega 3s.
Why doesn't anybody want Omega 3s? Not diabetics, not people with extremely high triglycerides, not people with high triglycerides, not normal people, nobody wants Omega 3s. Could it be that there are better options available? I hope so. That would be pathetic if the options currently available were not better than Omega 3s and people still demand those inferior options. Truth is, the options available are not inferior. You are delusional if you think Omega 3s are suddenly going to "perform miracles" for anybody.
Omega 3s have been out there and available for decades. No miracles found.
Pure EPA has been out there and available for decades. No miracles seen anywhere.
Vascepa is currently available. Type 2 diabetics can and do take it. People with extremely high triglycerides are taking it. Anybody who wants Vascepa can take it right now (off label).
So, people are already taking Vascepa and have been for 2 years. People have been taking Omega 3s for decades. People have been taking prescription pure EPA for decades. Guess what? No miracles.
No miracles happening bud.
Conclusions Among patients with ACS treated effectively with statins, fasting triglycerides predict long-term and short-term cardiovascular risk. Triglyceride-rich lipoproteins may be an important additional target for therapy. (A Study of RO4607381 in Stable Coronary Heart Disease Patients With Recent Acute Coronary Syndrome; NCT00658515)
Background Most patients with acute coronary syndrome (ACS) are treated with statins, which reduce atherogenic triglyceride-rich lipoproteins. It is uncertain whether triglycerides predict risk after ACS on a background of statin treatment.
Objectives This study examined the relationship of fasting triglyceride levels to outcomes after ACS in patients treated with statins.
Methods Long-term and short-term relationships of triglycerides to risk after ACS were examined in the dal-OUTCOMES trial and atorvastatin arm of the MIRACL (Myocardial Ischemia Reduction with Acute Cholesterol Lowering) trial, respectively. Analysis of dal-OUTCOMES included 15,817 patients (97% statin-treated) randomly assigned 4 to 12 weeks after ACS to treatment with dalcetrapib (a cholesteryl ester transfer protein inhibitor) or placebo and followed for a median 31 months. Analysis of MIRACL included 1,501 patients treated with atorvastatin 80 mg daily beginning 1 to 4 days after ACS and followed for 16 weeks. Fasting triglycerides at initial random assignment were related to risk of coronary heart disease death, nonfatal myocardial infarction, stroke, and unstable angina in models adjusted for age, sex, hypertension, smoking, diabetes, high-density lipoprotein cholesterol, and body mass index.
Results Fasting triglyceride levels were associated with both long-term and short-term risk after ACS. In dal-OUTCOMES, long-term risk increased across quintiles of baseline triglycerides (p 175/≤80 mg/dl) was 1.61 (95% confidence interval: 1.34 to 1.94). There was no interaction of triglycerides and treatment assignment on the primary outcome. In the atorvastatin group of MIRACL, short-term risk increased across tertiles of baseline triglycerides (p = 0.03), with a hazard ratio of 1.51 (95% confidence interval: 1.05 to 2.15) in highest/lowest tertiles ( 195/≤135 mg/dl). The relationship of triglycerides to risk was independent
I gotta admit clown-in-a-bag, that for being wrong 99.999% of the time, you sure are resilient. Where's the $0.50 I was supposed to get 6-months ago? I'd like to buy more at $1.30, that's for sure.